ABCC1 and cancer: Enzastaurin has been reported to display enhanced activity in combination with various anti-cancer drugs [see e.g. 11, 13, 17, 19, 41; 58–60] including ABCB1, ABCG2, and/or ABCC1 substrates such as paclitaxel [60], docetaxel [58], erlotinib [59], and doxorubicin [11].